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Edited by Jesus AvilaAbstract Phosphorylation of tau protein is regulated by several
kinases, especially glycogen synthase kinase 3b (GSK-3b),
cyclin-dependent protein kinase 5 (cdk5) and cAMP-dependent
protein kinase (PKA). Phosphorylation of tau by PKA primes
it for phosphorylation by GSK-3b, but the site-speciﬁc modula-
tion of GSK-3b-catalyzed tau phosphorylation by the prephosph-
orylation has not been well investigated. Here, we found that
prephosphorylation by PKA promotes GSK-3b-catalyzed tau
phosphorylation at Thr181, Ser199, Ser202, Thr205, Thr217,
Thr231, Ser396 and Ser422, but inhibits its phosphorylation at
Thr212 and Ser404. In contrast, the prephosphorylation had
no signiﬁcant eﬀect on its subsequent phosphorylation by cdk5
at Thr181, Ser199, Thr205, Thr231 and Ser422; inhibited it at
Ser202, Thr212, Thr217 and Ser404; and slightly promoted it
at Ser396. These studies reveal the nature of the inter-regulation
of tau phosphorylation by the three major tau kinases.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Neuroﬁbrillary degeneration is characterized by the abnor-
mal intracellular deposition of hyperphosphorylated microtu-
bule-associated protein tau in the form of paired helical
ﬁlaments (PHF) and straight ﬁlaments [1–3]. It is a common
feature of Alzheimer disease (AD) and several related neurode-
generative disorders [4] and correlates with the severity of
dementia in AD [5–7]. Many studies have demonstrated thatAbbreviations: AD, Alzheimer disease; PKA, cAMP-dependent protein
kinase; cdk5, cyclin-dependent protein kinase 5; GSK-3b, glycogen
synthase kinase-3b; NFT, neuroﬁbrillary tangles; PAGE, polyacryl-
amide gel electrophoresis; PHF, paired helical ﬁlaments; P-tau, tau
prephosphorylated by PKA
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doi:10.1016/j.febslet.2006.10.033abnormal hyperphosphorylation of tau is crucial to neuroﬁ-
brillary degeneration [4,8]. However, the molecular mecha-
nisms leading to abnormal tau hyperphosphorylation in AD
and other neurodegenerative diseases are not yet fully under-
stood.
Eﬀorts aiming to elucidate the mechanisms of abnormal tau
hyperphosphorylation have led to identiﬁcation of several pro-
tein kinases that may catalyze tau phosphorylation in the
brain. Among these tau kinase candidates, glycogen synthase
kinase 3b (GSK-3b), cyclin-dependent protein kinase 5
(cdk5) and cAMP-dependent protein kinase (PKA) have been
most implicated. The former two were actually described as
tau kinase I and tau kinase II, respectively [9,10]. These two ki-
nases can phosphorylate tau at multiple sites (for a summary
of the phosphorylation sites, see [11]). It has been observed
that prephosphorylation at certain sites primes tau to be a bet-
ter substrate in vitro [12–16] as well as in vivo [17] for GSK-3b.
These studies indicate the complexity of the regulation of tau
phosphorylation. Tau is hyperphosphorylated at as many as
37 sites in AD brain (see [11] for the list of phosphorylation
sites), but the eﬀect of priming on the phosphorylation of
tau by GSK-3b at most of the phosphorylation sites has not
been reported.
In this study, we investigated the eﬀects of prephosphoryla-
tion of tau by PKA on its subsequent phosphorylation by
GSK-3b or cdk5 at individual phosphorylation sites. We found
that PKA-induced tau phosphorylation promotes its subse-
quent phosphorylation at most sites catalyzed by GSK-3b,
whereas it diﬀerentially aﬀects its subsequent phosphorylation
by cdk5.2. Materials and methods
2.1. Materials
The catalytic subunit of PKA and GSK-3b was purchased from Sig-
ma (St. Louis, MO, USA) and CalBiochem (San Diego, CA, USA),
respectively. Recombinant cdk5 and p25 (an activator of cdk5) were
expressed, puriﬁed and reconstituted into an active holoenzyme, as de-
scribed previously [18]. The largest isoform of recombinant human tau,
tau441, was expressed and puriﬁed from Escherichia coli as described
previously [19]. The tau polyclonal antibody R134d against tau in a
phosphorylation-independent manner was raised in rabbits, as re-
ported previously [20]. Phosphorylation-dependent and site-speciﬁc
tau antibodies pT181, pS199, pS202, pT205, pT212, pS214, pT217,
pT231, pS262, pS396, pS404, pS409 and pS422 were purchased from
Biosource International (Camarillo, CA, USA). Monoclonal antibody
PHF-1 that recognizes tau phosphorylated at Ser396/Ser404 wasblished by Elsevier B.V. All rights reserved.
6270 F. Liu et al. / FEBS Letters 580 (2006) 6269–6274kindly provided by Dr. P. Davies of Albert Einstein College of
Medicine, Bronx, NY, USA. Peroxidase-conjugated anti-mouse and
anti-rabbit IgG were obtained from Jackson ImmunoResearch Labo-
ratories (West Grove, PA, USA); ECL Kit was from Amersham Phar-
macia (Costa Mesa, CA, USA); and [c-32P]ATP was from ICN
Biomedicals (Costa Mesa, CA, USA).Fig. 1. Eﬀect of prephosphorylation of tau by PKA on the subsequent
phosphorylation by GSK-3b and cdk5. Recombinant tau441 with
(P-tau, n) or without (s) prephosphorylation by PKA was incubated
withGSK-3b (left panel) or cdk5/p25 (right panel) for various periods of
time, followed by determination of tau phosphorylation by counting the
radioactivity after removing free [c-32P]ATP by ascending paper
chromatography.2.2. Phosphorylation of tau in vitroz
The in vitro phosphorylation was carried out by incubating tau441
(0.2 mg/ml) at 30 C in a phosphorylation reaction mixture. For
PKA-catalyzed phosphorylation, the reaction mixture contained
40 mM HEPES, pH 6.8, 10 mM b-mercaptoethanol, 10 mM MgCl2,
1.0 mM EGTA, and 0.2 mM ATP or [c-32P]ATP (500 cpm/pmol),
10 lg/ml PKA, and protease inhibitors (2 lg/ml aprotinin, 2 lg/ml
pepstatin, 5 lg/ml leupeptin, and 1.0 mM PMSF). For cdk5-catalyzed
phosphorylation, the reaction mixture contained 40 mM HEPES (pH
7.4), 10 mM b-mercaptoethanol, 10 mM MgCl2, 0.2 mM [c-
32P]ATP
(500 cpm/pmol), 6.4 lg/ml cdk5/p25 and protease inhibitors. For
GSK-3b-catalyzed phosphorylation, the mixture contained 40 mM
HEPES (pH 7.4), 10 mM MgCl2, 10 mM b-mercaptoethanol,
0.2 mM [c-32P]ATP (500 cpm/pmol), 0.4 lg/ml GSK-3b and protease
inhibitors. After incubation for various periods of time, the reaction
was stopped, the 32P-labeled tau was separated from free [c-32P]ATP
by paper chromatography, and the radioactivity of tau was determined
by Cerenkov counting, as described previously [21].
For prephosphorylation of tau with PKA, tau441 was phosphory-
lated, as described above, with non-radioactive ATP at 30 C for
90 min. Then, the reaction mixture was heated in boiling water for
5 min to inactivate PKA. The heat-treated mixture was brieﬂy centri-
fuged, and the resultant supernatant containing heat-stable tau441
was passed through a Sephadex G-50 minicolumn to exchange its buf-
fer into 40 mM HEPES (pH 7.4). Fractions containing P-tau were
pooled and stored at 20 C for further phosphorylation reaction with
GSK-3b or cdk5. Under this condition, approximately 2–2.5 mol of
phosphate were added to each mole of tau441. The non-prephosphory-
lated control tau441 was treated the same way except PKA was omitted
from the reaction mixture.2.3. Determination of site-speciﬁc phosphorylation of tau
For detecting site-speciﬁc phosphorylation of tau, the phosphoryla-
tion reactions were carried out with non-radioactive ATP, and the
reactions were stopped by adding 1/3 volume of fourfold concentrated
SDS–polyacrylamide gel electrophoresis (PAGE) sample buﬀer
(240 mM Tris–HCl, pH 6.8, 8.0% SDS, 20% b-mercaptoethanol,
40% glycerol and 0.08% bromophenol blue), followed by heating in
boiling water for 5 min. The phosphorylation of tau at each speciﬁc
site was detected by Western blots with various phosphorylation-
dependent and site-speciﬁc tau antibodies (at a dilution of 1:1000),
as described previously [22]. A phosphorylation-independent tau anti-
body, R134d (1:5000), was also used to detect total tau. For time
kinetic studies of tau phosphorylation, aliquots of reaction mixture
were removed, and the reaction was terminated by heating in a boiling
water bath for 5 min. After the mixture was cooled down, the phos-
phorylation of tau at each speciﬁc site was measured by using an im-
muno-dot-blot assay, as described [23].3. Results
To learn the overall eﬀect of prephosphorylation by PKA on
the subsequent phosphorylation of tau by GSK-3b or cdk5, we
ﬁrst phosphorylated tau with PKA and non-radioactive ATP
to a stoichiometry of 2–2.5, and then used this prephosphory-
lated tau (P-tau) and the control-treated tau in parallel as sub-
strates for subsequent phosphorylation by GSK-3b or cdk5.
We found that, under the conditions used, prephosphorylation
of tau with PKA increased its phosphorylation by GSK-3b
dramatically, but had no signiﬁcant eﬀect on cdk5-catalyzed
tau phosphorylation (Fig. 1). GSK-3b and cdk5 each phos-phorylated tau to a stoichiometry of nearly 1 after 90 min incu-
bation. In contrast, GSK-3b phosphorylated P-tau to
approximately 3 mol P/mol of tau in 90 min.
PKA, GSK-3b and cdk5 each can phosphorylate tau at mul-
tiple sites [11]. To examine the phosphorylation sites that are
modulated by prephosphorylation, we used Western blots
developed with phosphorylation-dependent and site-speciﬁc
tau antibodies to determine tau phosphorylation at various
sites after incubation of tau and P-tau with GSK-3b or cdk5.
We observed that pre-incubation of tau with PKA resulted
in strong immunostaining of tau with antibodies pS214,
pS262 and pS409 (Fig. 2, compare lane 4 with lane 3), indicat-
ing phosphorylation of tau at Ser214, Ser262 and Ser409 by
PKA. The increased immunostaining with these phosphoryla-
tion-dependent tau antibodies was speciﬁcally due to tau phos-
phorylation at these sites, because the same amount of tau was
loaded in each lane, as seen in R134d blot that detects total tau
protein. PKA-phosphorylated tau was not stained with anti-
bodies pT181, pS199, pS202, pT205, pT217, pT231, pS396,
pS404, pS422 or PHF-1 (Fig. 2). These results are consistent
with previous studies showing that Ser214, Ser262 and
Ser409 are major phosphorylation sites of tau by PKA
[15,24,25].
Analysis of the blots shown in Fig. 2 indicated that without
prephosphorylation, tau441 was phosphorylated by GSK-3b at
Ser199, Thr205, Thr212, Thr231, Ser396, Ser404 and Ser396/
Ser404 (PHF-1 sites; compare lane 2 with lane 3), and by
cdk5 at Ser199, Ser202, Thr205, Thr212, Thr217, Thr231,
Ser396 and Ser404 (compare lane 1 with lane 3). The site-spe-
ciﬁc phosphorylation of tau by these two kinases in the present
study is consistent with previous studies (summarized in [11]).
A remarkable upward shift of the apparent molecular weight
of tau after phosphorylation with these kinases was also seen
in the R134d (to total tau) blot, which further conﬁrmed
tau phosphorylation. When phosphorylation of tau and of
P-tau was compared, we found that prephosphorylation by
PKA dramatically promoted tau phosphorylation with GSK-
3b at Thr181, Ser199, Ser202, Thr205, Thr217, Thr231,
Ser396, and Ser422, but inhibited it at Ser404 (compare lane
5 with lane 2). In contrast, the prephosphorylation had no
detectable eﬀect on tau phosphorylation by cdk5 at Thr181,
Fig. 2. Site-speciﬁc eﬀects of prephosphorylation of tau by PKA on the subsequent phosphorylation by GSK-3b and cdk5. Recombinant tau441 was
ﬁrst phosphorylated by PKA, and then the phosphorylated tau (P-tau) and the control-treated tau (Tau) were further incubated with GSK-3b or
cdk5/p25 for 150 min. The phosphorylation of tau and P-tau at various phosphorylation sites was examined by Western blots developed with
phosphorylation-dependent and site-speciﬁc tau antibodies, as indicated under each blot.
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Thr212, Thr217 and Ser404; and slightly promoted it at
Ser396 (compare lane 6 with lane 1). The strong immunostain-
ing of lanes 5 and 6 in pS214, pS262 and pS409 blots resulted
from tau phosphorylation with PKA, because prephosphory-
lated tau without further treatment with GSK-3b or cdk5
had the same or even stronger staining with these antibodies
(compare lanes 5 and 6 with lane 4). These results suggest that
prephosphorylation of tau with PKA modulates its subsequent
phosphorylation in both site-speciﬁc and kinase-speciﬁc man-
ners.
To quantitate the site-speciﬁc eﬀects of PKA-induced prep-
hosphorylation on the subsequent phosphorylation of tau with
GSK-3b and cdk5, we investigated the phosphorylation-time
kinetics of the prephosphorylated and control-treated tau.
Tau phosphorylation at each individual phosphorylation site
at various time points was determined by an immuno-dot-blot
assay using the phosphorylation-dependent and site-speciﬁc
tau antibodies. We found that prephosphorylation of tau with
PKA dramatically increased GSK-3b-catalyzed phosphoryla-
tion at Thr181, Ser199, Ser202, Thr205, Thr217, Thr231,
Ser396 and Ser422, but inhibited the phosphorylation at
Thr212 and Ser404 (Fig. 3), which is consistent with the Wes-
tern blots shown in Fig. 2, except at Thr212. Because Ser214,Ser262 and Ser409 of tau are not phosphorylated by GSK-
3b or cdk5 [11], the time kinetics of phosphorylation at these
three sites were not studied by the immuno-dot-blot assay. It
is interesting to note that the prephosphorylation had an oppo-
site eﬀect on GSK-3b-catalyzed tau phosphorylation at the
adjacent sites Ser396 (stimulating) and Ser404 (inhibiting)
(Figs. 2 and 3). The immunoreactivity of tau with PHF-1, a
monoclonal antibody against the phosphorylated epitopes of
both Ser396 and ser404 of tau [26], was also increased slightly
after phosphorylation with PKA followed with GSK-3b
(Fig. 3), suggesting that this increase in PHF-1 immunoreactiv-
ity was due to tau phosphorylation at Ser396. This phenome-
non is consistent with the higher aﬃnity of PHF-1 to
phosphorylated Ser396 than to phosphorylated Ser404 of tau
[26].
Time kinetic analysis of cdk5-catalyzed tau phosphorylation
revealed that PKA-induced prephosphorylation had no signif-
icant eﬀect on cdk5-catalyzed phosphorylation at Thr181,
Ser199, Thr205, Thr231 or Ser422, but had an inhibitory eﬀect
on the phosphorylation at Ser202, Thr212, Thr217 and Ser404
(Fig. 4). The most marked inhibitory eﬀect was seen at Thr212
and Ser404. The only exception was Ser396 of tau, the phos-
phorylation of which was slightly promoted by PKA-catalyzed
prephosphorylation.
Fig. 3. Quantitation of the eﬀects of prephosphorylation by PKA on the subsequent phosphorylation at individual sites of tau by GSK-3b.
Tau441(Tau) and PKA-phosphorylated tau441 (P-tau) (0.2 mg/ml) were incubated with GSK-3b for various periods of time, and the phosphorylation
level of tau at each individual site was determined by using an immuno-dot-blot assay developed with phosphorylation-dependent and site-speciﬁc
tau antibodies, as indicated in each panel. All the data had been normalized with the amounts of tau protein, as determined by using
phosphorylation-independent tau antibody R134d.
Fig. 4. Quantitation of the eﬀects of prephosphorylation of tau by PKA on the subsequent phosphorylation at individual sites by cdk5/p25.
Tau441(Tau) and PKA-phosphorylated tau441(P-tau) (0.2 mg/ml) were incubated with cdk5/p25 for various periods of time, and the phosphorylation
level of tau at each individual site was determined by using an immuno-dot-blot assay developed with phosphorylation-dependent and site-speciﬁc
tau antibodies, as indicated in each panel. All the data had been normalized with the amounts of tau protein, as determined by using
phosphorylation-independent tau antibody R134d.
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The largest isoform of tau (441 amino acids) in human brain
contains 80 serine and threonine residues, and nearly half of
them are phosphorylated to certain extents in AD brain. Be-
cause the substrate speciﬁcities of protein kinases are com-
monly highly selective toward the primary sequences around
the acceptor serine and threonine residues, no single kinase
can phosphorylate all the abnormal hyperphosphorylation
sites of tau. Thus, more than one protein kinase must be in-
volved in the regulation of tau phosphorylation and in the
abnormal hyperphosphorylation of tau in AD brain. In addi-
tion, modiﬁcations of tau itself as a substrate protein, such
as glycosylation [22,23,27], also aﬀect tau phosphorylation.
Regulation of tau phosphorylation appears to be more com-
plex because phosphorylation of tau by one kinase modulates
the subsequent phosphorylation by others [12–17], although
the site speciﬁcity of such modulations has not been well stud-
ied. In the present study, we investigated such modulations by
the three most likely tau kinase candidates, GSK-3b, cdk5 and
PKA. To our knowledge, this is the ﬁrst thorough study on the
site-speciﬁc eﬀects of PKA-catalyzed phosphorylation on the
subsequent tau phosphorylation at more than 10 individual
phosphorylation sites catalyzed by GSK-3b and cdk5.
GSK-3b and cdk5 largely phosphorylate the same serine and
threonine residues of tau (for comparison, see [11]), but we
found in this study that its regulation by PKA-catalyzed prep-
hosphorylation is very diﬀerent. Prephosphorylation of tau by
PKA primes further phosphorylation by GSK-3b at most of
the phosphorylation sites, whereas it inhibits or has no eﬀect
on its subsequent phosphorylation by cdk5 at most of the
phosphorylation sites. It appears that the priming eﬀect is a
characteristic of GSK-3b-catalyzed phosphorylation, because
such an eﬀect has been observed with other GSK-3b substrates
such as glycogen synthase, the G-subunit and inhibitor-2 of
protein phosphatase 1, b-catenin, and transcription factors
CREB, eIF and NFAT [16,28,29]. However, the priming eﬀect
on GSK-3b-catalyzed tau phosphorylation does not follow the
pattern with other substrates, in which the primed phosphory-
lation sites are four amino acids N-terminal to the prephosph-
orylation sites (Ser/Thr-X-X-X-pSer/pThr) [30,31]. The primed
phosphorylation sites we observed in this study are not located
at the residues four amino acids N-terminal to the PKA-in-
duced tau phosphorylation sites (Ser214, Ser262 and Ser409).
Because antibody against phosphoserine at positions 210 and
258 of tau, which are four amino acids N-terminal to Ser214
and Ser262, is not available, we do not know whether these
two serine residues are phosphorylated by GSK-3b after prep-
hosphorylation with PKA. Position 405 of tau is a proline and
thus cannot be phosphorylated. Nevertheless, our results
showing the primed tau phosphorylation at several phosphor-
ylation sites outside the Ser/Thr-X-X-X-pSer/pThr motif sug-
gest that PKA-catalyzed phosphorylation could induce a
conformation change of tau that facilitates its further phos-
phorylation by GSK-3b at multiple sites. Our results indicate
that the modulation of GSK-3b-catalyzed tau phosphorylation
by prephosphorylation is site-speciﬁc. Actually, GSK-3b-cata-
lyzed phosphorylation of tau at 2 of 10 sites studied (Thr212
and Ser404) is inhibited rather than promoted by PKA-in-
duced prephosphorylation.
The eﬀects of prephosphorylation on cdk5-catalyzed phos-
phorylation of tau had not been investigated previously. Wefound that in contrast to GSK-3b, cdk5-catalyzed tau phos-
phorylation is either unaﬀected or inhibited (with the exception
of Ser396) by prephosphorylation with PKA. Therefore, the
modulations of tau phosphorylation by prephosphorylation
are not only site-speciﬁc, but also kinase-speciﬁc. These results
also suggest that despite the fact that these two kinases largely
catalyze phosphorylation of the same residues of tau protein,
they may have some diﬀerent catalyzing mechanisms and play
some diﬀerent roles in the regulation of tau phosphorylation.
Our ﬁndings provide detailed insight into the regulation of
GSK-3b- and cdk5-catalyzed phosphorylation of tau by its
prephosphorylation with PKA. In our previous study, we
found that injection of forskolin (a PKA activator) into the lat-
eral ventricle of rat brain not only induced tau phosphoryla-
tion at PKA sites, but also at Tau-1 (Ser198/Ser199/Ser202)
and PHF-1 (Ser396/Ser404) epitopes by the basal level of
GSK-3b activity [17]. We further conﬁrmed the involvement
of GSK-3b in tau phosphorylation at the Tau-1 and PHF-1
epitopes, because co-injection of LiCl (a GSK-3b inhibitor)
blocked forskolin-induced tau phosphorylation at these epi-
topes, whereas co-injection of ONU 112455A (an inhibitor
of cdc2 and cdk5) failed to block it [17]. Although this previous
study did not investigate individual GSK-3b-catalyzed phos-
phorylation sites of tau, it suggests that the regulation of
GSK-3b- and cdk5-catalyzed phosphorylation of tau by its
prephosphorylation with PKA, as we observed here in vitro,
occurs in vivo. Such regulation may also have important phys-
iological and pathological signiﬁcance, because the primed
phosphorylation by GSK-3b inhibits tau’s microtubule bind-
ing activity to a much larger extent than the non-primed phos-
phorylation [12,15] and, more importantly, impairs spatial
memory of the rats [17].
In conclusion, we have investigated quantitatively the mod-
ulation of GSK-3b- and cdk5-catalyzed tau phosphorylation
at individual phosphorylation sites by prephosphorylation
with PKA. We found that such modulations are both site-spe-
ciﬁc and kinase-speciﬁc. Our studies provide novel insight into
the mechanism of the complex regulation of tau phosphoryla-
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